A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A
NCT ID: NCT04683406
Last Updated: 2023-06-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
750 participants
INTERVENTIONAL
2020-12-28
2023-05-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A
NCT04024137
Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A
NCT07229820
Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A
NCT07229807
The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.
NCT03679143
A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza
NCT00705406
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ZSP1273 600 mg + Oseltamivir Placebo BID
Subjects received 5 doses of ZSP1273 at 600 mg once a day along with matching placebo of oseltamivir placebo orally twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days
ZSP1273 600 mg
3 X 200-mg tablet taken orally
Placebo to Oseltamivir
Placebo capsules matching oseltamivir2 X 75-mg
Oseltamivir 75mg + ZSP1273 Placebo
Subjects received 10 doses of Oseltamivir at a dose of 75 mg twice daily (BID) with matching placebo of ZSP1273 orally once a day with approximately 12 hour (+/- 2) intervals, over 5 days
Oseltamivir(oral)
2 X 75-mg tablet taken orally
Placebo to ZSP1273
Placebo capsules matching ZSP1273 600 mg
Placebo Comparator
Subjects received 5 doses of matching placebo of ZSP1273 and Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days
Placebo to Oseltamivir
Placebo capsules matching oseltamivir2 X 75-mg
Placebo to ZSP1273
Placebo capsules matching ZSP1273 600 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ZSP1273 600 mg
3 X 200-mg tablet taken orally
Placebo to Oseltamivir
Placebo capsules matching oseltamivir2 X 75-mg
Oseltamivir(oral)
2 X 75-mg tablet taken orally
Placebo to ZSP1273
Placebo capsules matching ZSP1273 600 mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female patient s aged ≥ 18 to ≤ 64 years at the time of signing the informed consent/assent form
3. Patients with a diagnosis of influenza virus infection confirmed by all of the following
* Positive Rapid Antigen Test (RAT) with throat swabs;and
* Fever ≥ 38ºC (axillary) in the predose examinations or \> 4 hours after dosing of antipyretics if they were taken;and
* At least one of the following general systemic symptoms associated with influenza are present with a severity of moderate or greater I. Headache II. Feverishness or chills III. Muscle or joint pain IV. Fatigue
* At least one of the following respiratory symptoms associated with influenza are present with a severity of moderate or greater I. Cough II. Sore throat III. Nasal congestion
4. The time interval between the onset of symptoms and the predose examinations is 48 hours or less. The onset of symptoms is defined as either
* Time of the first increase in body temperature (an increase of at least 1ºC from normal body temperature)
* Time when the patient experiences at least one general or respiratory symptom
5. Women of childbearing potential (WOCBP) who agree to use a highly effective method of contraception for 3 months after the first dose of ZSP1273 or oseltamivir
Exclusion Criteria
2. Patients aged ≥ 18 years with known allergy to oseltamivir (Tamiflu) or ZSP1273
3. Patients unable to swallow tablets or capsules or any medical history in gastrointestinal that interferes with the absorption of drugs
4. Patients who have received antiviral medication including peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir, or amantadine within 7 days prior to the predose examinations
5. Patients who have received Chinese patent medicine or herbal medicine with antiviral effect within 7 days prior to the predose examinations
6. Patients who have received Anti-influenzal prescription within 7 days prior to the predose examinations
7. Subject who produces purulent sputum or has suppurative tonsillitis.
8. White blood cells(WBC)\>10.0×109/L at screening.
9. Chest X - ray examination confirmed bronchitis,pneumonia,pleural effusion or pulmonary interstitial lesions.
10. Patients who have experienced respiratory tract infection,Otitis media,nasosinusitis.
11. Patients with severe or uncontrollable underlying diseases:blood disorders,severe chronic obstructive pulmonary disease(COPD),liver disorders(ALT or AST≥3 ULN,total bilirubin≥1.5 ULN),kidney disorders(serum creatinine\>177μmol/L or 2mg/dL),chronic congestive heart failure(NYHA III-IV),mental disorders
12. Immunodeficiency,including malignant tumor,organ or marrow transplant,human immunodeficiency virus \[HIV\] infection,or patients receiving immunosuppressant therapy 3 months prior to enrollment.
13. Concomitant therapy with aspirin or salicylic acid.
14. Patients weighing \< 40 kg or morbid obesity(Body mass index \[BMI\]≥30kg/m2)
15. Known history of alcohol abuse or drug abuse
16. Pregnancy or breastfeeding at screening and during the study.All female subjects of childbearing potential must have a negative urine pregnancy test at screening and during the trial.
17. Have received any other investigational products within 3 months prior to dosing.
18. Patients who, in the opinion of the investigator, would be unlikely to comply with required study visits, self-assessments, and interventions
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangdong Raynovent Biotech Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of bengbu medical college
Bengbu, Anhui, China
Xuancheng People's Hospital
Xuancheng, Anhui, China
Beijing Chaoyang Hospital,Capital Medical University
Beijing, Beijing Municipality, China
Beijing Ditan Hospital Capital Medical University
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
People's Hospital of Cuanjiang, Chongqing
Chongqing, Chongqing Municipality, China
Third Military Medical University
Chongqing, Chongqing Municipality, China
Quanzhou First Hospital
Quanzhou, Fujian, China
Fujian Provincal Hospital
Xiamen, Fujian, China
Xiamen Hospital of T.C.M
Xiamen, Fujian, China
Xiamen Zhongshan Hospital
Xiamen, Fujian, China
Dongguan People's Hospital
Dongguan, Guangdong, China
Foshan First People's Hospital
Foshan, Guangdong, China
Shunde University of Southern Medical University
Foshan, Guangdong, China
Guangdong Province Traditional Chinese Medical Hospital
Guangzhou, Guangdong, China
Nanfang Hospital
Guangzhou, Guangdong, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
The First Affiliated Hospital Of Guangzhou Medical University
Guangzhou, Guangdong, China
Huizhou Central People's Hospital
Huizhou, Guangdong, China
Jieyang People's Hospital
Jieyang, Guangdong, China
Qingyuan People's Hospital
Qingyuan, Guangdong, China
Shantou Central Hospital
Shantou, Guangdong, China
Yuebei People's Hospital
Shaoguan, Guangdong, China
Shenzhen Luohu Hospital Group Luohu People's Hospital
Shenzhen, Guangdong, China
Shenzhen People's Hospital
Shenzhen, Guangdong, China
Songgang People's Hospital
Shenzhen, Guangdong, China
Nanning First People's Hospital
Nanning, Guangxi, China
Guizhou Provicial People's Hospital
Guiyang, Guizhou, China
Affiliated Hospital Zunyi Medical College
Zunyi, Guizhou, China
First Hospital of Qinhuangdao
Qinhuangdao, Hebei, China
Huaihe Hospital of Henan University
Huaihe, Henan, China
Luoyang Central Hospital Affiliated To Zhengzhou University
Luoyang, Henan, China
Nanyang Central Hospital
Nanyang, Henan, China
Nanyang First People's Hospital
Nanyang, Henan, China
The Second People's hospital of Nanyang
Nanyang, Henan, China
The Third Affiliated Hospital of Nanyang Medical College
Nanyang, Henan, China
The Third Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China
Henan Provicial People's Hospital
Zhengzhou, Henan, China
Zhengzhou Central Hospital
Zhengzhou, Henan, China
Zhengzhou Sixth Hospital
Zhengzhou, Henan, China
Yiyang Central hospital
Yiyang, Hunan, China
Nanjing First Hospital
Nanjing, Jiangsu, China
Nanjing Jiangning Hospital
Nanjing, Jiangsu, China
Sir run run Hospital Nanjing Medical University
Nanjing, Jiangsu, China
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
First Affiliated Hospital of Gannan Medical University
Ganzhou, Jiangxi, China
Jiujiang University Affiliated Hospital
Jiujiang, Jiangxi, China
First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
The Second Affiliated Hospital Of Nanchang University
Nanchang, Jiangxi, China
The Third Hospital Of Nanchang
Nanchang, Jiangxi, China
Pingxiang People's Hospital
Pingxiang, Jiangxi, China
Shangyao People's Hospital
Shangyao, Jiangxi, China
The First Hospital Of Jilin University
Changchun, Jilin, China
General Hospital of Liaohe Oilfield
Panjin, Liaoning, China
Shenyang Central Hospital Affiliated To Shenyang medical college
Shenyang, Liaoning, China
Binzhou Medical University Hospital
Binzhou, Shandong, China
Heze Municipal Hospital
Heze, Shandong, China
Jinan Central Hospital
Jinan, Shandong, China
Liaocheng People's Hospital
Liaocheng, Shandong, China
Linyi People's Hospital
Linyi, Shandong, China
Shandong Energy Zaozhuang Mining
Zaozhuang, Shandong, China
PKUCare luzhong Hospital
Zibo, Shandong, China
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Shanxi Bethune Hospital
Taiyuan, Shanxi, China
Chengdu Xinhua Hospital
Chengdu, Sichuan, China
General Hospital of Western Theater of PLA
Chengdu, Sichuan, China
Sichuan Provicial People's Hospital
Chengdu, Sichuan, China
The Third People's Hospital of Wuhou, Chengdu
Chengdu, Sichuan, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Dazhou Central Hospital
Dazhou, Sichuan, China
Affiliated Hospital of North Sichuan College
Nanchong, Sichuan, China
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
The first People hospital of Yunnan Province
Kunming, Yunnan, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Ruian People's Hospital
Ruian, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Yang Z, Zhan Y, Li Z, Lin Z, Fang Z, Li H, Chen X, Ding B, Zeng H, Zhang X, Song Y, Lin Z, Liang S, Luo J, Huang J, Chen X, Zhong N; Onradivir Trial Recruitment and Medical Monitoring Group. Efficacy and safety of onradivir in adults with acute uncomplicated influenza A infection in China: a multicentre, double-blind, randomised, placebo-controlled and oseltamivir-controlled, phase 3 trial. Lancet Respir Med. 2025 Jul;13(7):597-610. doi: 10.1016/S2213-2600(25)00046-3. Epub 2025 Jun 7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZSP1273-20-06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.